This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Diagnosis of Active Tuberculosis by ELISPOT

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2005 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
Information provided by:
National Taiwan University Hospital Identifier:
First received: September 13, 2005
Last updated: NA
Last verified: July 2005
History: No changes posted
Recent studies revealed that the ex vivo enzyme-linked immunospot (ELISPOT) assay for gamma interferon is a specific method for contact tracing of Mycobacterium tuberculosis infection. However, its use in endemic area and bacillus Calmette-Guérin (BCG)-vaccinated hosts has not been proved. We hypothesize that the TB-ELISPOT assay can be a rapid and accurate diagnostic tool for active tuberculosis in clinical suspects in Taiwan.


Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Official Title: Diagnosis of Active Tuberculosis in Endemic Area by Using Enzyme-Linked Immunospot Assay for Gamma-Interferon

Resource links provided by NLM:

Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 200
Study Start Date: August 2005
Estimated Study Completion Date: December 2006

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who present with fever or respiratory symptoms (cough, dyspnea, or hemoptysis) lasting for ≥ 2 weeks and have compatible radiographic findings were considered clinical suspects of TB.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00174083

Contact: Jann-Yuan Wang, MD 886-2-23562905

National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Jann-Yuan Wang, MD    886-2-23562905   
Contact: Li-Na Lee, PhD    886-2-23563905   
Principal Investigator: Jann-Yuan Wang, MD         
Sponsors and Collaborators
National Taiwan University Hospital
Principal Investigator: Jann-Yuan Wang, MD physician
  More Information

Publications: Identifier: NCT00174083     History of Changes
Other Study ID Numbers: 9461700717
Study First Received: September 13, 2005
Last Updated: September 13, 2005

Keywords provided by National Taiwan University Hospital:
Tuberculosis, TB-ELISPOT, active tuberculosis latent infection interferon

Additional relevant MeSH terms:
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents processed this record on August 18, 2017